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WITHDRAWN
NeuRologIcAl DIsoRDeRs – cost studies
PND17
AlemTuzumAb buDgeT ImPAcT ANAlysIs IN RelAPsINg-RemITTINg 
mulTIPle scleRosIs IN THe us
Celestin C.1, Wandstrat T.1, Coleman C.I.2
1Genzyme, a Sanofi company, Cambridge, MA, USA, 2University of Connecticut/Hartford Hospital 
Evidence-Based Practice Center, Hartford, CT, USA
OBJECTIVES: In the phase 3 CARE-MS II study (NCT00548405), alemtuzumab dem-
onstrated a reduction in annualized relapse rate (49%) and sustained accumulation 
of disability (42%) versus subcutaneous interferon beta-1a 44 μ g (both P< 0.01). This 
analysis assessed the budget impact (BI) of adding alemtuzumab to a formulary 
containing approved disease-modifying therapies (DMTs) for multiple sclerosis (MS) 
in a hypothetical 100,000-member US health plan. METHODS: Alemtuzumab was 
administered as 2 annual treatment courses to patients with relapsing-remitting 
MS inadequately responding to prior therapy, with as-needed retreatment in an 
extension (NCT00930553). A 5-year BI analysis from a US payer perspective was 
developed with US-approved DMTs included as comparators. The model accounted 
for the effect of DMTs on relapses, but not disability. Key cost inputs included drug 
acquisition, drug administration and monitoring, adverse events (AEs), and cost 
of relapse. Percentage of patients taking alemtuzumab was projected to increase 
gradually from 1.6% in its first year of use to 7.5% by Year 5. RESULTS: Relapse costs 
were reduced beginning the first year of alemtuzumab formulary inclusion, resulting 
in annual relapse cost savings of $25,045 by Year 5. Total costs attributable to DMT 
acquisition, AEs, and monitoring increased with the introduction of alemtuzumab 
($188,516 by Year 5). Total budget impact peaked in Year 4 (plan member per month 
[PMPM] cost= $0.17) and decreased by Year 5 (PMPM= $0.14). This downward trend is 
attributable to decreased drug acquisition and administration costs due to the dura-
bility of alemtuzumab’s effect and increased relapse cost savings. CONCLUSIONS: 
Reduction in relapses, the unique dosing schedule, and durable efficacy for most 
patients in the absence of retreatment, provide significant cost offsets to alemtu-
zumab formulary inclusion compared to formularies not including alemtuzumab. 
The model provides conservative estimates by excluding disability costs, which are 
a major contributor to the cost of caring for MS patients.
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buDgeT ImPAcT of ADDINg PegINTeRfeRoN beTA-1A To THe foRmulARy 
foR THe TReATmeNT of RelAPsINg foRms of mulTIPle scleRosIs
Mauskopf JA1, Graham J2, Fay-Azhar M3, Kinter E3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI-Health Solutions, Research Triangle 
Park, NC, USA, 3Biogen Idec, Weston, MA, USA
OBJECTIVES: To estimate the budget impact of adding peginterferon beta-1a, a new 
interferon requiring injections only every two weeks for the treatment of relapsing 
forms of multiple sclerosis (MS), to a managed care formulary in the US. METHODS: 
An Excel model was developed to compare the drug-related costs of the current mix 
of treatments with the costs of an estimated treatment mix including peginter-
feron beta-1a for a managed care organization (MCO) with 1,000,000 covered lives. 
The number of people with relapsing forms of MS was estimated using published 
prevalence data. Treatment share of peginterferon beta-1a was assumed to increase 
from 3% in 2014 to 7% in 2018 taken proportionately by treatment shares from the 
other interferons indicated for MS. Drug costs included: acquisition costs adjusted 
by patient payments and dispensing fees as well as administration, monitoring, 
and adverse event costs. Annual relapse treatment costs were estimated using the 
relative risk reduction of a relapse for each DMT derived using a mixed-treatment 
comparison analysis A one-way sensitivity analysis was performed. RESULTS: The 
resonance imaging and clinical outcomes. Despite challenges in comparing out-
comes across studies, exploratory analyses of treatment effects can be compared 
informally using relative reductions in a specific endpoint. The number needed to 
treat (NNT) to prevent an event is an important outcome to consider for any com-
parisons within the field of MS. METHODS: NNTs were derived using data from 
studies with teriflunomide 14 mg (TEMSO, NCT00134563; TOWER, NCT00751881) or 
DMF (DEFINE, NCT00420212; CONFIRM, NCT00451451) based on the inverse of abso-
lute differences between treatment and placebo groups. RESULTS: Teriflunomide 
studies included patients with progressive disease; patients in DEFINE had slightly 
lower baseline Expanded Disability Status Scale scores. Teriflunomide and DMF 
significantly reduced risk of relapse (all studies). NNTs to prevent 1 relapse were 
similar across all studies (5.9 [TEMSO], 5.6 [TOWER], 5.3 [DEFINE], 5.6 [CONFIRM]). 
Risk of disability progression sustained for 12 weeks was significantly reduced in 
TEMSO, TOWER, and DEFINE but not CONFIRM. Corresponding NNTs to prevent 
disability progression were 13.8, 17.4, 10.8, and 30.2. Risk of relapse leading to hos-
pitalization was significantly reduced in TEMSO and TOWER but not in DEFINE and 
CONFIRM. Corresponding NNTs were lower in TEMSO (12.5) and TOWER (20) than 
in DEFINE (50) and CONFIRM (50). Safety data and corticosteroid use will be pre-
sented. CONCLUSIONS: Using the NNT approach, we demonstrate a comparable 
effect size for teriflunomide and DMF on relapses. NNTs to prevent disability pro-
gression with teriflunomide showed a consistent significant reduction in risk vs 
placebo in both TEMSO and TOWER. For DMF, comparable NNTs were observed only 
in DEFINE, and not in CONFIRM. Reduction of risk for relapse leading to hospitaliza-
tion was significant only for teriflunomide.
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INTeRfeRoN-Â THeRAPIes foR THe TReATmeNT of mulTIPle scleRosIs IN 
bRAzIl: A sysTemATIc RevIeW WITH meTA-ANAlysIs
Junqueira M.1, Clark O.A.2, Wong S.3, Fujii R.K.1
1Merck Serono, São Paulo, Brazil, 2Evidências - Kantar Health, Campinas, Brazil, 3EMD Serono, 
Inc., Billerica, MA, USA
OBJECTIVES: In Brazil, there are three first line interferonβ for relapsing remit-
ting multiple sclerosis (RRMS): Interferonβ 1a (Rebif® and Avonex®) and 1b 
(Betaferon®). Our aim is to produce a systematic review with meta-analysis 
to compare those Interferon’s-β efficacies in RRMS. METHODS: We searched 
MEDLINE, CENTRAL and others database to identify randomized controlled trials 
evaluating Interferons-β in RRMS. Clinical outcomes evaluated were reduction of 
relapse risk at 12, 24 months, and reduction of disability progression measured 
by the Expanded Disability Status Scale. Aggregated data was evaluated using 
a series of pairwise fixed-effects meta-analyses. RESULTS: From 465 articles 
found, 9 fit the inclusion criteria (5 placebo-controlled and 4 head-to-head tri-
als). The analysis showed that Rebif® reduces relapses at 12 months (RR= 0,85; 
95%CI= 0.77-0.93; P= 0.0005), 24 months (RR= 0.85; 95%CI= 0.77-0.92; P= 0.0002) and 
disability progression at 24 months (RR= 0.76; 95%CI= 0.61-0.95; P= 0.02) compared 
to placebo. Betaferon® reduces relapses at 24 months (RR= 0.89; 95%CI= 0.81-0.99; 
P= 0.03) but does not differ significantly from placebo in relapses over 12 months 
or disability progression. Avonex® does not differ significantly from placebo at 
any endpoint. From the 4 head-to-head trials: two compared Betaferon® and 
Avonex® showing Betaferon® superior in reducing disability progression at 24 
months (RR= 0.76; 95%CI= 0.59-0.9; P= 0.03); one comparing Rebif® to Avonex® 
showed superiority of Rebif® in decreasing relapses at 24 months and time to 
first relapse; one showed no differences in annual relapses between Betaferon® 
and Rebif®. CONCLUSIONS: Betaferon® did not reduce relapse risk in 12 months 
and disability progression. Avonex® did not demonstrate significant reduction 
in relapse risk reduction at 12 and 24 months as well as reduction of disability 
progression when compared to placebo. Among the approved first-line treatment 
interferon-β only Rebif® demonstrate statistically significant lower risk of relapse 
in 12 and 24 months as well as reduction in disability progression.
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bAyesIAN mIxeD TReATmeNT comPARIsoN of eARly TReATmeNT foR 
PARkINsoN DIseAse: AN INDIRecT comPARIsoN
Marquez M.1, Diaz J.P.2, Ibarra A.1, Pizarro M.3, Cervantes A.4, Rodríguez M.4, Soto H.1
1Universidad Autonoma Metropolitana, México D.F., Mexico, 2Universidad Nacional Autonoma 
de Mexico, México D.F., Mexico, 3Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico, 
4Instituto Nacional de Neurología y Neurocirugía, México D.F., Mexico
OBJECTIVES: Parkinson’s disease (PD) is a neurodegenerative disorder causing pro-
gressive motor impairment and disability. The effects of PD are measure throughout 
the Unified Parkinson’s Disease Rating Scale (UPDRS). PD treatments include drugs 
that increase the functional ability of the underactive dopaminergic system or that 
reduce the excessive influence of excitatory cholinergic neurons. The purpose of this 
study was to conduct an indirect comparison of the efficacy of different alternatives 
of early treatment for Parkinson’s disease regarding the UPDRS. METHODS: We 
realized a systematic literature review in eigth data base with keys word: Parkinson 
disease, early treatment, levodopa, pramipexole, rasagiline, selegiline and placebo. 
The inclusion criteria were patients with parkinson’s disease in Hoehn and Yahr I, 
2 or 3, UPDRS scale, lenguaje spanish and english, since January 1994 to May 2014. 
Results of all trials were analyzed simultaneously with a Bayesian Mixed Treatment 
Comparison (MTC) to obtain the relative efficacy into the treatments. RESULTS: 
There were 1080 clinical trials (CT), only five meeting the inclusion criteria: levodopa 
(1CT), pramipexole (1 CT), rasagiline (2CT) and selegiline (1CT), using a random 
model levodopa showed the best punctuation in UPDRS (probability= 0.61) when all 
the treatments were compared. Also, it showed a mean difference of 7 relative to 
placebo, CrI (0.14-14); 2.2 relative to pramipexole CrI (-7.5- 12); 3.5 relative to rasagil-
ine, CrI (-4.8-12) and 1.6 relative to selegiline, CrI (-8.3-12). CONCLUSIONS: Findings 
of this study indicate that Levodopa provides a greater disability and impairment 
reduction in patients with Parkinson disease (measured by UPDRS) patients than 
pramipexole, rasagiline and selegiline as first treatment option to early parkinson’s 
disease in monotherapy.
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mapped to MedDRA Preferred Terms with BioPortal and ICD9Data.com. Focus was 
limited to EudraVigilance Important Medical Event ADRs. Evaluate Pharma (evalu-
ategroup.com) provided usage data. From January 2011 through December 2013, 
either the most costly “primary suspect” ADR or outcome cost was assigned to each 
case report. Individual report costs were summed for each drug and then divided 
by exposure rates to obtain downstream costs per patient. Eight drugs prescribed 
to treat multiple sclerosis (MS) were analyzed in detail. RESULTS: From lowest to 
highest, average downstream costs per patient exposed were: glatiramer acetate 
($86); dalfampridine ($248); interferon beta-1b ($404); dimethyl fumarate ($552); 
fingolimod ($563); interferon beta-1a (Avonex) ($1,045); interferon beta-1a (Rebif) 
($1,419); and natalizumab ($2,345). It should be noted that under reporting to FAERS 
may result in under estimation of the costs above. CONCLUSIONS: Post-marketing 
ADRs and poor outcomes represent a significant safety issue and cost burden for 
the healthcare industry. The method outlined here used post-marketing data and 
specific cost estimates to compare serious side effect costs across MS drugs. Future 
work may include analyzing other drug classes and using claims data for ADR and 
outcome frequency estimates.
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AN AssessmeNT of fAcToRs AssocIATeD WITH HIgH cosTs AmoNg 
PATIeNTs WITH mulTIPle scleRosIs (ms) ReceIvINg DIseAse-moDIfyINg 
DRug (DmD) THeRAPy
Locklear JC1, Frean M2, Phillips AL1, Menzin J2
1EMD Serono, Inc., Rockland, MA, USA, 2Boston Health Economics, Inc., Waltham, MA, USA
OBJECTIVES: Compare patient characteristics and frequency of diagnoses between 
high-cost and non‒high-cost MS patients receiving DMDs. METHODS: MS patients 
(aged 18–63; ≥ 1 MS diagnosis claim:ICD-9-CM:340.xx) with ≥ 1 DMD claim (first 
claim= index date) and continuous eligibility 12 months pre- and post-index were 
identified from a random sample of 5 million lives in the IMS LifeLink Plus database 
from 1/1/2007–6/30/2012. Patients with all-cause total costs (excluding DMD costs) 
≥ 75th percentile were considered high-cost. Diagnoses potentially associated 
with costs (“condition indicators”) were grouped into three domains: MS-related 
conditions (e.g., disability), Clinical Classification System (CCS) code categories 
(e.g., gastrointestinal), Charlson-Deyo comorbidities. Fisher and Wilcoxon tests 
were used in unadjusted statistical comparisons. Logistic regression was used to 
evaluate likelihood of being a high-cost patient. Covariates included demograph-
ics, condition indicators, dalfampridine use, newly initiating DMDs and adher-
ence. RESULTS: Analysis included 24,815 patients. 75th percentile for high-cost 
status was $11,740, yielding 6207 high-cost and 18,608 non‒high-cost patients 
(mean age:46.3 vs 44.2, respectively; p< 0.001). In unadjusted analyses, percentage 
of patients with each condition indicator was statistically significantly higher in 
the high-cost group (p< 0.05). In logistic regression analyses, age and sex were 
not consistently predictive of being high-cost. High counts of conditions within 
each domain (e.g., ≥ 5 MS-related conditions: odds ratio [OR]:5.801; p< 0.0001) and 
selected individual conditions (e.g., disability: OR:1.809; p< 0.0001) were associ-
ated with significantly higher likelihood of being high-cost. Dalfampridine use, 
a symptomatic agent, was also significantly associated with being high-cost 
(OR:5.744–6.062 across specifications; p< 0.0001). Conversely, better adherence 
(medication possession ratio ≥ 80%) and newly initiating DMDs were associated 
with lower likelihood of being high-cost (OR:0.570–0.594 and 0.850–0.898 across 
specifications, respectively; all p< 0.01). CONCLUSIONS: MS-related conditions, 
CCS categories and Charlson-Deyo comorbidities were independently associated 
with high costs. Interventions targeting individuals affected by key conditions 
may be important for reducing costs and disease burden.
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A comPARIsoN of HeAlTHcARe ResouRce uTIlIzATIoN AND AssocIATeD 
cosTs IN ADulTs WITH geNeRAlIzeD coNvulsIve seIzuRes (gcs)
Li X1, Barghout V2, Wang Z3
1Eisai, Inc., Woodcliff Lake, NJ, USA, 2VEB Healthcare LLC., Morristown, NJ, USA, 3Eisai Inc., 
Woodcliff Lake, NJ, USA
OBJECTIVES: Generalized convulsive seizures (GCS), including clonic, myoclonic, 
and tonic-clonic seizures, account for 40% of epilepsy seizures. Patients with GCS, 
especially uncontrolled disease, may accrue significant healthcare resource utiliza-
tion and associated costs. These parameters were estimated in adult patients with 
GCS. METHODS: Adults (≥ 18 years) with ≥ 2 GCS claims (ICD-9 code: 345.1x) 30 days 
apart during index year were identified from OptumInsight® claims database (2011-
2013). Continuous enrollment in their US healthcare plan (medical and pharmacy 
benefit) for ≥ 1 year before and after index date was required. Eligible patients were 
categorized as having stable disease (no change in anti-epileptic drug [AED] over 
12 months) or uncontrolled disease (added AED to an existing regimen). Index date 
was selected during calendar year 2012 (stable disease, convenience date; uncon-
trolled disease, date of additional AED initiation). Pharmacy and medical claims 
during post-index year were used to estimate overall and epilepsy-related resource 
utilization and costs. Analysis of covariance was used to compare outcomes after 
adjusting for baseline differences between groups. RESULTS: Annual estimates 
were based on 1,201 patients (1,067 stable/134 uncontrolled): mean age, 40 years; 
female sex, 54%/55%; and mean Charlson comorbidity index, 0.70/0.90. Inpatient 
and outpatient ER rates were 15.6% (epilepsy-related 10.6%) and 32.0% (epilepsy-
related 15.9%) for stable patients, and 23.9% (epilepsy-related 22.4%) and 42.5% 
(epilepsy-related 27.6%) for uncontrolled patients. Associated mean costs were 
substantially less for stable ($16,487; epilepsy-related, $6,570) than uncontrolled 
($30,648; epilepsy-related, $16,102) patients. After adjusting for baseline characteris-
tics, the difference was significantly less: $10,928 (P= 0.0006); epilepsy-related $8,769 
(P< 0.0001). CONCLUSIONS: Patients with uncontrolled GCS accrue significantly 
more healthcare resource utilization. Uncontrolled GCS patents have considerably 
higher costs for both total and epilepsy related than stable patients (39%, total 
overall annual costs, 57%, epilepsy related). Early and effective disease manage-
ment of patients with uncontrolled GCS may mitigate the high economic burden.
estimated budget impact of adding peginterferon beta-1a to the formulary was 
negative for the first 5 years: in 2014, with a treatment share of 3.0%, the estimated 
budget decrease was 0.07% of the total annual costs for DMT-related and relapse 
treatment costs and a decrease of $0.005 per member per month (PMPM); in 2018, 
with a treatment share of 7%, the estimated budget decrease was 0.23% of the 
total annual costs and a decrease of $0.014 PMPM. Sensitivity analyses showed 
that the model was most sensitive to the acquisition costs of peginterferon beta-
1a. CONCLUSIONS: Under model assumptions for market shares, adding peginter-
feron beta-1a to the MCO formulary would result in a small decrease in MCO costs 
for patients with relapsing forms of MS.
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HosPITAl buDgeT ImPAcT of sugAmmADex (bRIDIoNÂ®) foR ReveRsAl of 
NeuRomusculAR blockADe
Insinga R., Maiese E.M., Devine S.
Merck & Co., Inc., Kenilworth, NJ, USA
OBJECTIVES: To estimate the budget impact of sugammadex within a typical US 
hospital. METHODS: A model was developed to evaluate budget impact of using 
sugammadex instead of neostigmine or spontaneous reversal in a subset of hospital 
procedures. Sugammadex utilization was projected to be highest in procedures 
with deep neuromuscular block (NMB) throughout, and patients at elevated risk of 
post-operative respiratory complications. Inputs included costs of NMB and reversal 
agents, operating room (OR) procedure time, value of OR time, risks and costs of 
residual neuromuscular blockade (RNMB) and associated complications, and reduc-
tions in RNMB with sugammadex use. Because trials have shown sugammadex’s 
impact on OR time and RNMB varies by whether full neuromuscular recovery (train-
of-four [TOF] ratio ≥ 0.9) is verified prior to extubation in the OR, two scenarios were 
modeled, evaluating when recovery to TOF ≥ 0.9 is verified prior to extubation and 
when it is not. RESULTS: When all patients are verified to have full neuromuscular 
recovery (TOF ≥ 0.9, no RNMB) prior to extubation, sugammadex saved an average 
of 24 minutes in the OR per procedure, with a net cost savings provided at least 10% 
of OR time saved can be converted to increased throughput. When no patients are 
verified to have full recovery prior to extubation, sugammadex saved 1 minute in the 
OR per procedure; while reducing the risk of RNMB from 47% to 3%. The incidence of 
post-operative aspiration, hypoxemia, muscle weakness or upper airway obstruction 
was reduced from 86 per 100 procedures, to 36 per 100 among patients receiving 
sugammadex, at an average incremental cost of $66 per procedure. CONCLUSIONS: 
Budget impact of sugammadex was found to vary according to practices for neu-
romuscular monitoring and extubation. Use of sugammadex can ameliorate the 
current trade-off between OR efficiency and occurrence of RNMB when utilizing 
neostigmine or spontaneous reversal.
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buDgeT ImPAcT of cHosINg RebIf® As THe INTeRfeRoN of cHoIce foR THe 
TReATmeNT of RelAPsINg-RemITTINg mulTIPle scleRosIs IN THe bRAzIlIN 
PublIc HeAlTHcARe sysTem
Fujii R.K.1, Wong S.2, Junqueira M.1
1Merck Serono, São Paulo, Brazil, 2EMD Serono, Inc., Billerica, MA, USA
OBJECTIVES: Currently the clinical protocols for the treatment of relapsing-
remitting multiple sclerosis of the public sector in Brazil do not differentiate the 
interferonβ options available (Avonex®, Betaferon® or Rebif®). Considering the data 
presented in a meta-analysis by Filippini et al in 2013, a budget impact analysis 
was developed to understand the impacts of recommending the use of Rebif® as 
the interferon of choice. METHODS: A transition model was developed under the 
assumption that patients experiencing a relapse would have a 50% chance of switch-
ing to another line of therapy. Each treatment relapse rate was calculated from the 
Philippini 2013 meta-analysis information regarding the risk of having a relapse 
in 24months, using the formulae developed by Zhang and Yu, 1998. Such formula 
calculates the relative risk from odds ratio information using the “assumed control 
risk”, which was calculated by the pondered average rate of relapses occurring in 
all related trials’ placebo arms. Only 2014 direct medical costs were considered, 
including medications and hospital costs obtained at the DATASUS database. The 
number of patients was estimated by the number of treatments provided at the year 
of 2014, and the time horizon was defined as 5 years. Market shares were calculated 
from the 2014 public purchases information and the compared scenarios were the 
current practice versus an alternative scenario where Rebif® was considered the 
interferon of choice. RESULTS: Current scenario represents BRL1,288.32 million 
in first and second line medications, BRL219.00 million in third line medications, 
and BRL20.46 million in relapses’ acute care. Alternative scenario could represent 
BRL1,300.51 million in first and second line medications, BRL201.16 million in third 
line medications and BRL19.94 million in relapses’ acute care. CONCLUSIONS: Total 
savings with the new scenario were BRL 6.16 million, mainly by reducing relapses 
and delaying the start of more expensive third line medications.
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cAlculATINg THe cosTs of ADveRse DRug ReAcTIoNs fRom PosT-
mARkeTINg DATA: ImPlIcATIoNs foR ouTcomes ReseARcH
Hoffman KB, Dimbil M
AdverseEvents, Inc., Santa Rosa, CA, USA
OBJECTIVES: Adverse Drug Reactions (ADRs) and outcomes observed during homog-
enous pre-approval clinical trials frequently do not correlate with real-world expe-
rience. The substantial costs associated with ADRs and poor outcomes represent 
a significant burden to the healthcare system. Frequency estimates coupled with 
specific ADR and outcome costs may provide a way to compare downstream impact. 
This study sought to estimate the post-marketing costs associated with ADRs and 
outcomes for individual drugs by combining: 1) ADR and outcome-specific costs, 2) 
data from the FDA’s Adverse Event Reporting database (FAERS), and 3) drug usage 
information. METHODS: ADR and outcome data were obtained from FAERS. ADR 
and outcome costs were obtained from AHRQ. ICD-9 codes for ADR costs were 
